ArticleScientific reports2021
High prevalence of bla
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Biofilm, virulence, and ESBL-mediated resistance: unmaskingMicrobiology spectrum · 2026Article
- Genotypic and phenotypic evidence of extended-spectrum β-lactamase and carbapenemase-producing shigatoxigenic and intimin-producing Escherichia coli in diarrheic calves in Bangladesh: A hidden zoonotic and public health risk.Veterinary research communications · 2026Article
- Multimatrix surveillance of multidrug-resistant and ESBL-producingVeterinary world · 2026Article
- Fitness costs and persistence of plasmid-mediated cephalosporin resistance inFrontiers in microbiology · 2026Review
- Detection of Selected Extended-Spectrum β-Lactamase (ESBL) Genes inVeterinary medicine international · 2026Article
- Prevalence of ESBL-producingOne health (Amsterdam, Netherlands) · 2025Review
- Incidence of extended spectrum beta-lactamase (ESBL) producingIranian journal of microbiology · 2025Article
- Investigation of Bacterial Infections and Antibiotic Resistance Patterns Among Clinical Isolates in the Center of Iran.International journal of microbiology · 2025Article
- Article
- Risk Factors for ESBL-ProducingVeterinary medicine international · 2025Article
- The Global Rise of ESBL-ProducingAnimals : an open access journal from MDPI · 2024Review
- Current epidemiologic features and health dynamics of ESBL-producingBiosafety and health · 2024Review
- Article
- Determination of Multi-Class Antimicrobial Residues and Antimicrobial Resistance in Cow Milk and Feces Samples during Withdrawal Period.Animals : an open access journal from MDPI · 2023Article
- Antimicrobial Resistance and Clonal Lineages ofAntibiotics (Basel, Switzerland) · 2023Review
- Molecular Epidemiology of Extended-Spectrum Beta-Lactamase and AmpC ProducingAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterobacteria that produce extended-spectrum β-lactamase (ESBL) such as Escherichia coli (E. coli) are common in our environment and known to cause serious health implications in humans and animals. β-lactam antibiotics such as penicillins, cephalosporins and monobactams are the most commonly used anti-bacterials in both humans and animals, however, Gram negative bacteria (such as E. coli) that produces extended-spectrum β-lactamases (ESBLs) have the ability to hydrolyze most β-lactams therefore making them resistant to β-lactam antibiotics. Recent extensive researches on the epidemiology and genetic characteristics of extended-spectrum β-lactamase (ESBL)-producing E. coli reported the existence of ESBL-producing E. coli in humans, companion animals and poultry. Therefore, this experiment was performed to investigate the prevalence and genetic characteristics of β-lactamase producing E. coli isolated from beef cattle farms in the Sichuan-Chongqing circle of China. Phenotypic confirmation of ESBL-producing E. coli was performed using the double disk synergy test. Polymerase Chain Reaction (PCR) was used to detect bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.